EGFR and cancer: Afatinib is the first irreversible multi-targeted TKI, functioning by selectively inhibiting EGFR and HER-2 and thereby attenuating the downstream oncogenic signaling pathways correlated with cancer proliferation, invasion, metastasis and angiogenesis.